Newsroom

Download PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients –    -Tivozanib-Nivolumab Combination Generally Well Tolerated –   – Data to be Presented at the ESMO 2019 Annual Congress –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 23, 2019– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the

Download PDF – 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm – – Company Plans to Discuss Updated Results with FDA – – AVEO to Host Conference Call Today at 8:00 am Eastern Time – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 10, 2019– AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO continues to make meaningful clinical, regulatory and strategic progress across our pipeline,”

Download PDF TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 1, 2019– Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an amendment to the terms of the 2006 tivozanib license agreement

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2019– AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois. Presentation Details Title: Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancerFirst Author: Wendy M. Swetzig, PhD, Northwestern University Feinberg School of MedicineAbstract Number: 5538Poster

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 9, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA® (tivozanib) milestone from EUSA, AVEO’s strengthened balance sheet provides us with a cash runway that we expect will take us

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 1, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. The conference is being held May 7-8 in New York. About AVEO AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines